Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer

Marcia S. Brose, C. Benedikt Westphalen, Xiaoyun Pan, Vadim Bernard-Gauthier, Milena Kurtinecz, Helen Guo, Virginie Aris, Neil R. Brett, Abdelali Majdi, Vivek Subbiah, Nathan A. Pennell, Kenneth L. Kehl, Alexander Drilon

Open source

DOI
10.1200/po-24-00500
Published
2025-04
Container
JCO Precision Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1200/po-24-00500,
  title = {Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer},
  author = {Marcia S. Brose and C. Benedikt Westphalen and Xiaoyun Pan and Vadim Bernard-Gauthier and Milena Kurtinecz and Helen Guo and Virginie Aris and Neil R. Brett and Abdelali Majdi and Vivek Subbiah and Nathan A. Pennell and Kenneth L. Kehl and Alexander Drilon},
  year = {2025},
  journal = {JCO Precision Oncology},
  doi = {10.1200/po-24-00500},
  url = {https://doi.org/10.1200/po-24-00500}
}

RIS

TY  - JOUR
TI  - Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer
AU  - Marcia S. Brose
AU  - C. Benedikt Westphalen
AU  - Xiaoyun Pan
AU  - Vadim Bernard-Gauthier
AU  - Milena Kurtinecz
AU  - Helen Guo
AU  - Virginie Aris
AU  - Neil R. Brett
AU  - Abdelali Majdi
AU  - Vivek Subbiah
AU  - Nathan A. Pennell
AU  - Kenneth L. Kehl
AU  - Alexander Drilon
PY  - 2025
JO  - JCO Precision Oncology
DO  - 10.1200/po-24-00500
UR  - https://doi.org/10.1200/po-24-00500
ER  - 

APA

Brose, M. S., Westphalen, C. B., Pan, X., Bernard-Gauthier, V., Kurtinecz, M., Guo, H., Aris, V., Brett, N. R., Majdi, A., Subbiah, V., Pennell, N. A., Kehl, K. L., & Drilon, A. (2025). Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-24-00500

Source records